Thursday, 26 August 2010

Inhibition of mutated, activated BRAF in metastatic melanoma

This article is getting a lot of press attention. It appears that mutations in the gene encoding the serine-threonine protein kinase B-RAF are a good target for treating melanoma skin cancer.

Flaherty et al. report a multi-centre, phase 1 trial of the inhibitor PLX4032. Eighty percent of patients with the BRAF mutations responded to treatment where as those without didn't.

This has great potential for targeted individual treatment for melanoma patients with the mutated gene. Further laboratory and clinical trials are planned.

Keith T. Flaherty et al. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma. N Engl J Med 2010; 363:809-819 (August 26, 2010). Find the article here.

No comments:

Post a Comment